Αρχική World News The Cancer Moonshot: Moving from Planning to Research

The Cancer Moonshot: Moving from Planning to Research

November 19, 2018, by Dinah Singer, Ph.D.

A female technician working at a genomic sequencing machine.

A research technician from the Advanced Technology Research Facility at NCI’s Frederick National Laboratory for Cancer Research.

Credit: National Cancer Institute

The Cancer MoonshotSM was announced in 2016 with three overarching goals: accelerate progress in cancer research, encourage greater collaboration, and improve the sharing of data. More than 2 years later, the foundation has been laid for achieving those goals.

A critical component of that foundation was the Moonshot Blue Ribbon Panel, which engaged in a thoughtful and thorough process to develop a comprehensive report that laid out a series of recommendations to get us to those goals. In December 2016, Congress passed the 21st Century Cures Act, which allocated $1.8 billion over 7 years to transition the Moonshot from an ambitious idea to a reality.

NCI rapidly established a systematic process for implementing the report’s recommendations. These efforts have resulted in the launching of a series of new scientific programs and the awarding of close to $600 million to research teams across the country. Each of the recommendations of the Blue Ribbon Panel are being addressed through these programs.

As the Moonshot moves forward, I want to provide an update to the cancer community about the science being supported by the Moonshot, because it is the science that will accelerate progress across the entire cancer continuum.

The Science Begins

The Blue Ribbon Panel’s recommendations covered 10 areas that the panel of experts, based on their extensive deliberations and feedback solicited from across the cancer community, felt were poised for progress if additional funding could be made available.

NCI staff led the effort to operationalize those recommendations, forming working groups and using a variety of mechanisms to develop funding opportunities aligned with each recommendation. Currently, most of fiscal years’ 2017 and 2018 funds have been awarded, and the next phase of the Moonshot—the research phase—is well underway.

Cancer immunotherapy is one example. Although progress in immunotherapy has been swift in recent years, the panel felt that, with an infusion of funds, even further advancement would be possible.

Under the Moonshot, NCI is funding two groups of research teams: one focused on immunotherapeutic approaches in adults and the other in children. The Immuno-Oncology Translational Network—which includes 31 principal investigators at 19 different institutions—is investigating the mechanisms by which tumors in adults interact with the immune system, developing new immune-based therapies, and creating approaches for minimizing the risk of treatment side effects.

Because most pediatric cancers are biologically quite different from adult cancers, a separate network of research teams has been established that will focus their efforts on identifying immune targets and treatments specific to pediatric cancers and developing laboratory models for testing immunotherapies against these cancers.

Also built into the immunotherapy component of the Moonshot is a data management center, which will allow researchers to share their work easily and facilitate collaboration. This is not unique to the immunotherapy recommendation. Data management centers are being established for other Moonshot-funded research networks as well.

The data management centers for these different networks will interact with each other, sharing data, information, and resources. They are central to public access and data sharing policy established for the Moonshot, which emphasizes the importance of investigators rapidly making available published studies that result from their Moonshot-funded research, including their primary data.

The panel also made recommendations for advancing progress in cancer prevention and early detection. Some of the research being funded in this area will make extensive use of implementation science—taking evidence-based interventions and testing ways to apply them in real-world settings. For example, several research teams will test ways to improve smoking cessation in economically disadvantaged populations where tobacco use remains stubbornly high.

Similarly, the uptake of colorectal cancer screening is low among certain populations, including several racial/ethnic minority groups. A Moonshot-funded initiative is tackling this issue directly, with research teams conducting pilot studies of approaches to improve both screening in underserved populations and the necessary clinical follow-up from that screening.

Supporting a Broad Spectrum of Investigation

The Moonshot is also focused on supporting fundamental research that will further improve our understanding of cancer.

One such example is the Human Tumor Atlas Network (HTAN), a collaborative network that includes investigators at 10 research centers and one data management center. Using a broad range of tools and technologies, these research teams will perform intensive analyses of tumor and tissue samples to construct 3-dimensional maps of human cancers. These maps will capture how cancers change over time—from a precancerous lesion to established tumor to resistant tumor to metastasis—and describe the composition of the types of cells within and around a tumor and the genetic makeup of those cells.

Research teams being funded will focus on highly aggressive pediatric cancers (e.g., neuroblastoma and glioblastoma), on cancer types that disproportionately affect minority and underserved populations (e.g., breast, lung), and on cancers that often have a hereditary component (e.g., colon).

The Blue Ribbon Panel also recognized that accelerating progress against a disease as complicated as cancer requires greater collaboration among researchers and a more efficient research process. One recommendation, for example, was the creation of a network for directly engaging patients. The network’s aim will be to make it possible for any patient diagnosed with cancer to have their tumors molecularly profiled and be preregistered for any clinical trials for which they might become eligible.

An essential component of this patient network will be a biobank for storing tumor samples, other tissue specimens, and associated patient data. Special emphasis will be given to include rare tumors. In fact, under the Moonshot, an NCI research team has already launched a pilot project, called NCI-CONNECT, for people diagnosed with rare central nervous system tumors.

Dinah Singer, Ph.D.
Co-Chair, Cancer Moonshot Blue Ribbon Panel
NCI Acting Deputy Director

Credit: National Cancer Institute

Moonshot research teams may be able to take advantage of core services, such as genomic analyses or the formulation of drug candidates for laboratory testing, available through NCI via contracts, including through the Frederick National Laboratory for Cancer Research.

A Foundation for Progress

As co-chair of the Moonshot Blue Ribbon Panel, I’m extremely pleased by what we’ve been able to accomplish in such a short period, with a process marked by a true spirit of collaboration and collegiality.

NCI leadership is committed to maintaining that collaborative spirit, and to managing the Moonshot in a way that will provide the stability and continuity necessary to allow research to continue at a swift pace and help to achieve the rapid gains envisioned for this effort. We’re also committed to keeping the cancer research community fully informed as the Moonshot moves forward.

With these new research initiatives, the Moonshot is already well on its way to achieving its goals and having a lasting impact on cancer research.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

News digest – ovarian cancer blood test, statins, spending review and head and neck cancer immunotherapy

Ovarian cancer blood test ‘better than previously thought’   A new investigation into an existing blood test to detect ovarian cancer has uncovered better-than-expected...

Woman with Nonverbal Autism Diagnosed with Breast Cancer After Caregiver Sister Finds Lump

Tabitha Cyrus, whose friends and family affectionately call her Taffy, was three years old when she was diagnosed with autism. Her family had anticipated...

Living With Metastatic Breast Cancer: How I Reinvented Myself

Shonte Drakeford is a 36-year-old Washington, D.C. native, nurse practitioner, United States Army wife, and German Shepherd mama. She was diagnosed with stage IV...

The Mediterranean Diet

The Mediterranean diet is a predominately plant based diet that accents omega 3 rich fish sources and whole foods that are minimally processed. Olives...

Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination Therapy in the S1320 Study

Opposite to the initial study hypothesis, the results of the S1320 indicate that intermittent dosing of BRAF/MEK inhibitor combination did not improve progression-free survival...

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours for Larotrectinib

On 23 October 2020, the US Food and Drug Administration (FDA) approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine, Inc.) as a...